Millennium Management LLC Has $580,000 Stake in Immunic, Inc. (NASDAQ:IMUX)

Millennium Management LLC grew its stake in Immunic, Inc. (NASDAQ:IMUX) by 480.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 579,683 shares of the company’s stock after purchasing an additional 479,846 shares during the period. Millennium Management LLC owned about 0.64% of Immunic worth $580,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its holdings in shares of Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after acquiring an additional 177,542 shares during the period. Barclays PLC bought a new position in shares of Immunic during the 4th quarter worth about $84,000. Invesco Ltd. bought a new position in shares of Immunic during the 4th quarter worth about $37,000. Focus Partners Wealth lifted its holdings in shares of Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after acquiring an additional 23,610 shares during the period. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after acquiring an additional 22,200 shares during the period. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Stock Performance

IMUX opened at $0.79 on Monday. The company has a fifty day moving average price of $0.96 and a two-hundred day moving average price of $1.05. Immunic, Inc. has a 52 week low of $0.56 and a 52 week high of $2.11. The firm has a market capitalization of $75.54 million, a PE ratio of -0.64 and a beta of 1.48.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, hitting analysts’ consensus estimates of ($0.25). Equities analysts forecast that Immunic, Inc. will post -0.94 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on IMUX shares. William Blair reissued an “outperform” rating on shares of Immunic in a report on Friday, May 16th. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Thursday, May 1st. B. Riley reissued a “buy” rating and set a $5.00 price target (down from $6.00) on shares of Immunic in a report on Friday, May 23rd. Finally, Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Immunic presently has a consensus rating of “Buy” and a consensus target price of $11.60.

Immunic Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.